@cbronsonmd's hCG and enclomiphene claims, fact-checked

What did @cbronsonmd actually say?

The claim is straightforward: hCG and enclomiphene are useful tools, but they eventually stop working for most hypogonadal men. He calls this "tachyphylaxis" to hCG, describing it as becoming "insensitive to it." His conclusion is blunt: for men who want to avoid injectable testosterone, "all roads eventually lead back to testosterone."

This is a common clinical position among hormone specialists, and it deserves scrutiny rather than automatic acceptance. The mechanisms he's gesturing at are real, but the inevitability he implies is where things get complicated. Let's look at what the evidence actually shows.

Does the science back this up?

Partially. The tachyphylaxis claim for hCG has genuine biological plausibility, but the clinical evidence is thinner than the confident framing suggests. For enclomiphene, the picture is more nuanced and actually more favorable than he implies.

Human chorionic gonadotropin works by mimicking luteinizing hormone (LH) at the Leydig cell receptor. Chronic supraphysiologic LH receptor stimulation can downregulate receptor expression, a mechanism documented in animal models and inferred in human clinical settings. However, large controlled trials specifically quantifying the rate and timeline of hCG tachyphylaxis in hypogonadal men are sparse. A study by Liu et al. (2002, Journal of Clinical Endocrinology and Metabolism) showed sustained Leydig cell response over several months, complicating the "inevitable" narrative. Enclomiphene, a selective estrogen receptor modulator, works upstream by blocking estrogen feedback at the hypothalamus. Wiehle et al. (2014, Andrology) demonstrated that enclomiphene maintained testosterone levels comparable to topical testosterone over 3 months, with preserved LH and FSH, suggesting the hypothalamic-pituitary axis remains responsive, at least in the short term.

What did they get wrong (or right)?

He gets the mechanism directionally right but oversimplifies it. Tachyphylaxis is a real concern with long-term hCG use, particularly at higher doses, but framing it as something that happens to "a lot of people" without citing rates or timelines is vague enough to mislead.

Where he's more clearly wrong is lumping enclomiphene into the same inevitability argument. Enclomiphene doesn't stimulate the LH receptor directly, so it doesn't carry the same tachyphylaxis risk profile as hCG. Treating them as equivalent in terms of long-term failure is not well supported. He also deserves credit for acknowledging legitimate reasons to avoid injectable testosterone, particularly fertility preservation. Men on exogenous testosterone experience suppression of the hypothalamic-pituitary-gonadal axis, which can reduce sperm count significantly. Masterson et al. (2019, Fertility and Sterility) confirmed that hCG co-administration helps preserve spermatogenesis during TRT. That clinical nuance is accurate and worth acknowledging.

What should you actually know?

If you're hypogonadal and want to avoid injectable testosterone, the story is more complicated than "it won't work forever." Some men do respond well to enclomiphene or clomiphene long-term, particularly those with secondary hypogonadism where the testes are functional but the signaling is impaired. Primary hypogonadism, where the testes themselves are damaged or deficient, is a different situation entirely, and there hCG and enclomiphene are less likely to produce lasting results regardless of tachyphylaxis.

The honest clinical reality is that response varies significantly by underlying diagnosis, age, baseline testosterone, and individual receptor sensitivity. Blanket statements about all roads leading back to testosterone may describe a common clinical trajectory, but they don't describe every patient. For men with secondary hypogonadism and fertility goals, working with a specialist to monitor LH, FSH, and testosterone over time, and adjusting protocols based on actual lab values, is more informative than accepting inevitability upfront.

• Tachyphylaxis with hCG is plausible but not as universally documented in humans as the confident framing implies.
• Enclomiphene has a different mechanism than hCG and shouldn't be grouped into the same failure narrative.
• Underlying diagnosis matters enormously: secondary hypogonadism responds better to these alternatives than primary hypogonadism.
• Fertility preservation is a legitimate and well-supported reason to explore hCG and enclomiphene before committing to exogenous testosterone.